The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study

• Published in: PloS one Vol. 10; no. 7; p. e0132048
• Main Authors: Kolko, Miriam, Horwitz, Anna, Thygesen, John, Jeppesen, Jørgen, Torp-Pedersen, Christian
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 16.07.2015; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Age; Age Distribution; Aged; Aged, 80 and over; Aging; Analogs; Child; Child, Preschool; Denmark - epidemiology; Drugs; Female; Glaucoma; Glaucoma - drug therapy; Glaucoma - epidemiology; Hospitals; Humans; Identification methods; Incidence; Infant; Infant, Newborn; Male; Medical personnel; Middle Aged; Ophthalmology; Patients; Population; Prescription drugs; Prevalence; Prevalence studies (Epidemiology); Prostaglandins - therapeutic use; Registries; Studies; Sympathomimetics; Systematic review; Trends; Young Adult; Denmark
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0132048

The purpose of the present study was to describe the prevalence, incidence and geographic variation of glaucoma in Denmark in the period from 1996 to 2011. Moreover, the aim was to identify the treatment patterns of glaucoma within the studied period. All Danish citizens were included throughout the study period. The National Prescription Registry was used to identify all claimed prescriptions for glaucoma medication. A total of 116,592 incident glaucoma patients were identified. Average age at onset was 66 years (range: 0-105 years), 55% were women. The prevalence of glaucoma increased from 0.79% to 1.72% during the investigated period. In 2011 glaucoma affected 3.76% of the population above 50 years and 10% in patients above 80 years. The age-specific incidence rate of glaucoma seemed to be constant and the increasing prevalence was primarily attributed to an aging population. We found the highest prevalence of glaucoma in the capital region of Denmark. Within the studied period the use of prostaglandin analogs and combination drugs increased, whereas the use of β-blockers, carbon anhydrase inhibitors and parasympathomimetic drugs decreased (p<0.001). Finally, the use of α2-adrenergic agonists remained unchanged. A total of 75% of the patients were treated with two or more glaucoma medications. Over all, the present study is the first to assess the frequency and the development of glaucoma in Denmark over a 15-year period. We find that glaucoma affects a little less than 2% of the total population and increases with age to reach a prevalence of more than 10% amongst people above 80 years. Generally, the present study is the largest nation-wide study ever made and must be a close-to-real-life-picture of the utilization of glaucoma medication on a national scale. Our findings confirm other recent estimations on an increasing burden of glaucoma globally.